Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 17;8:979. doi: 10.1038/s41598-018-19147-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Selected N-glycan traits from serum (Se) and effluent (Ef) over time. (A and B) Mean ± SE values of all patients over time classes as defined in Table 1. (A) At baseline (study month 0) all p-values were below the Bonferroni-adjusted significance threshold α = 0.0042 in paired Wilcoxon signed-rank tests for serum vs. effluent for A2G, A2E, A3E, A2F, IgG-related traits (N = 85 each); A3F was not significantly different at baseline. (C and D) Min/Max-values and boxplots with p-values from a paired Wilcoxon signed-rank test (two-tailed) for IgG-related direct traits in effluent samples from 24 patients at baseline vs. 24 months.